Thus the in vitro condition serves to identify TGF-β target genes, but it does not indicate the direction of their regulation in the in vivo context and hence cannot predict the critical issue of biological outcome (tumor suppression vs. tumor progression). The gene discussed is TGFB1; the disease is neoplasm.